Skp2 is an F-box protein involved in the ubiquitination and subsequent degradation of the cyclin-dependent kinase (Cdk) inhibitor p27. Skp2 has been reported to be overexpressed in a variety of cancer types and to correlate with poor prognosis. We have identified a novel isoform of Skp2 we named Skp2B, which differs from Skp2 only in the C-terminal domain and unlike Skp2 localizes to the cytoplasm. Here, we describe the relative expression of both Skp2 and Skp2B in breast cancer cell lines and in primary breast cancers using quantitative real time RT-PCR. We show that Skp2B mRNA is expressed 10-fold less than Skp2 mRNA in the immortalized but nontransformed breast cell line, 184B5. However, Skp2B is overexpressed as frequently as Skp2, and to higher levels than Skp2 in breast cancer cell lines and primary cancers. Further, we show that cytoplasmic staining is frequent in primary breast cancers. In addition, we found that xenografts expressing Skp2B grow faster than xenografts expressing low levels of Skp2B, and that this effect is independent of p27 degradation. These findings therefore suggest that Skp2B overexpression is also observed in breast cancers and identify Skp2B as a putative oncogene.
Introduction
Linkage of ubiquitin to a protein is a highly organized process involving the sequential action of an ubiquitinactivating enzyme (E1), an ubiquitin-conjugating enzyme (E2) and an ubiquitin-ligase (E3). This enzymatic cascade results in the attachment of a polyubiquitin chain onto specific lysine residues of a substrate, which serves as a signal for degradation by the 26S proteasome. Most of the regulation of the ubiquitination pathway occurs at the level of the ubiquitin ligase.
Of particular interest to this study is the SCF ubiquitin ligase complex (Bai et al., 1996; Kipreos et al., 1996; Feldman et al., 1997; Zhou and Howley, 1998) that is composed of Skp1, a cullin, an F-box protein and the ring finger protein Roc-1, which is required to bring the E2 into the complex (Ohta et al., 1999; Skowyra et al., 1999; Joazeiro and Weissman, 2000) . The existence of several cullins and F-box protein complexes offers the potential for the combinatorial assembly of many SCF complexes (Krek, 1998; Patton et al., 1998) ; however, the precise number of distinct SCF complexes remains unknown. F-box proteins act as adaptors by associating with substrate proteins, bringing them to the core of the SCF by binding to Skp1 (Skowyra et al., 1997) . The SCF Skp2 complex refers to the SCF in which Skp2 is the F-box protein.
Skp2 is involved in the ubiquitin-dependent degradation of the cyclin-dependent kinase (Cdk) inhibitor p27 (Carrano et al., 1999; Sutterluty et al., 1999) . p27 binds to and inhibits Cyclin E-Cdk2 complexes, and as a result, prevents progression through the cell cycle. Upon phosphorylation of threonine-187, p27 binds to Cks1 and Skp2 (Harper, 2001) , becomes ubiquitinated and subsequently degraded. Consequently, the degradation of p27 leads to the activation of Cyclin E-Cdk2 complexes and hence entry into the S phase of the cell cycle. Loss of p27 is a frequent event in several cancer types and is associated with poor prognosis (Loda et al., 1997; Gstaiger et al., 2001; Signoretti et al., 2002) . The loss of the p27 expression is often associated with increased degradation due to the overexpression of Skp2 (Gstaiger et al., 2001) and Cks1 (Inui et al., 2003; Masuda et al., 2003; Shapira et al., 2004) .
Skp2 has three important domains. The first is the F-box motif, which is situated at the N-terminus of the protein, and the second consists of 10 consecutive leucine-rich repeats (LRR), located near the C-terminus. The F-box is required for binding to Skp1, while the LRR are required for binding to substrates. The third important domain is the C-terminus, as it folds back near the F-box and stabilizes the interaction with Skp1. This is supported by the observation that a partial deletion of the C-terminus of Skp2 reduces its association with Skp1.
We have isolated a splice variant of Skp2, which we originally called Skp2-CTV (C-terminal variant) as it is characterized by the presence of a unique C-terminal domain (Ganiatsas et al., 2001) . In order to simplify the nomenclature, we have now renamed this variant Skp2B. We found that Skp2B differs from Skp2 in several respects, notably that Skp2B is cytoplasmic while Skp2 is nuclear. Interestingly, since the isolation of Skp2B, a number of studies using antibodies that recognize both Skp2 and Skp2B have described the presence of strong cytoplasmic staining of Skp2 in various cancer types (Penin et al., 2002; Signoretti et al., 2002; Dowen et al., 2003; Drobnjak et al., 2003) . Cytoplasmic staining of Skp2 was observed in breast cancer (Signoretti et al., 2002) , although the percentage of cytoplasmic versus nuclear staining was not reported in this study. In prostate cancer within the AfricanAmerican population, however, cytoplasmic Skp2 staining was found to be predominant. Moreover, the lack of correlation between Skp2 and p27 levels in a large number of these cases led the authors to conclude that Skp2 expression in prostate cancer pathogenesis might not be exclusively related to p27 degradation (Drobnjak et al., 2003) . One obvious hypothesis is that they were detecting the expression of the cytoplasmic Skp2B, which would explain this discrepancy. In agreement with this conclusion, two additional studies, one in Kaposi's sarcoma and another in cervical cancer, found no correlation between Skp2 expression and loss of p27. Further, both of these studies reported a significant percentage of cytoplasmic staining of Skp2, which also suggests that Skp2B overexpression in these tumors may explain their observations (Penin et al., 2002; Dowen et al., 2003) .
We therefore initiated this study to determine the relative expression of Skp2 and Skp2B in breast cancer cell lines and in primary breast cancer samples. We show here that while Skp2B mRNA is expressed at lower levels than Skp2 mRNA in the immortalized but nontransformed breast cell line 184B5 and normal breast tissue, Skp2B is overexpressed as frequently as Skp2 and to higher levels than Skp2 in breast cancer cell lines and primary cancers. Further, we show that cytoplasmic staining is frequent in primary breast cancers. In addition, we show that a cell line stably expressing Skp2B promotes xenograft formation in nude mice, but that this effect is independent of p27 degradation. Therefore, these results suggest that Skp2B overexpression participates in the formation of these cancers by targeting proteins other than p27 for degradation.
Results
Skp2 and Skp2B are overexpressed in breast cancer cell lines and in primary breast cancers
In order to determine the relative expression of Skp2 and Skp2B, we first designed primers for both isoforms and tested their specificity using plasmids expressing either Skp2 or Skp2B cDNAs as templates in a PCR reaction. For Skp2 amplification, the forward primer corresponded to a sequence that is present in both Skp2 and Skp2B cDNA (Figure 1a and c) , while the reverse primer corresponded to a sequence unique to Skp2 C-terminal domain ( Figure 1a ). We found that this combination of primers allowed the amplification of Skp2 but not Skp2B or any other unrelated product (Figure 1b) . Likewise, for amplification of Skp2B, the forward primer was the same as the primer used for Skp2 amplification, while the reverse primer was specific to the C-terminal domain of Skp2B (Figure 1c ). This later combination was found to lead to the specific amplification of Skp2B but not Skp2 or any other unrelated product (Figure 1d ). The sequences of the PCR products were confirmed by sequencing. The primers were further characterized using serial dilutions of Skp2 or Skp2B plasmid as template in a real time PCR reaction. In both cases, we found a direct Figure 1 Skp2 and Skp2B cDNA amplification. DNA sequence of Skp2 (a) or Skp2B (c). The sequences of their respective C-terminal domains are indicated in blue, the forward PCR-primer in red and the reverse primer in green. (b) In total, 10 ng of pcDNA3 and pcDNA3 encoding either Skp2 or Skp2B were used in a PCR reaction using the Skp2 primers. (d) In total, 10 ng of pcDNA3 and pcDNA3 encoding either Skp2 or Skp2B were used in a PCR reaction using the Skp2B primers Skp2B is overexpressed in breast cancer S Radke et al correlation between the number of cycles at which a product is first detected and the concentration of plasmid DNA (data not shown).
The primers were then used to determine Skp2 and Skp2B mRNA levels in human breast cell lines by quantitative real time RT-PCR. The breast cell line 184B5 was used as our normal control as this cell line is immortalized but nontransformed, while T47-D, SUM159, HS578T, MCF-7 and ZR75.1 were used as breast cancer cell lines. Total RNA was isolated from each cell line and equal amounts of RNA used in a real time RT-PCR reaction using either Skp2 or Skp2B specific primers. We found that Skp2 mRNA was detected as early as cycle 18 (Figure 2a) , while the earliest detection of Skp2B mRNA was at cycle 23 ( Figure 2c ). We estimated that Skp2 levels are 9.98-fold more elevated compared to Skp2B mRNA levels in the nontransformed breast cell line 184B5, indicating that the endogenous expression of Skp2 is higher than Skp2B. For comparison of the expression levels between cell lines, the level of expression of Skp2 or Skp2B found in 184B5 cells was set to the arbitrary value of 1 and the expression levels found in all other cell lines calculated relative to this value (Figure 2b and d) . We define overexpression as a level of expression higher than in 184B5 cells. We found that Skp2 mRNA level was equal or lower than in the normal control in four out of five cancer cell lines tested, while its level was significantly higher than normal in HS578T ( Figure 2b ) (P ¼ 0.024). For Skp2B, the expression was lower than in normal cells in two of the breast cancer cell lines and higher in three, including SUM159 (P ¼ 0.04) and MCF-7 (P ¼ 0.02) cells (Figure 2d) .
We expanded the quantitative real time RT-PCR analysis of Skp2 and Skp2B expression levels using total RNA from two normal breast tissues, three benign breast tumors and eight breast cancers. Skp2 expression was detected in both normal samples and the highest level of expression of the two normal breast samples was set at a value of 1 such that overexpression is defined as a level of expression higher than the highest level of expression found in normal breast sample. Skp2 expression in the three benign tumors was found to be equal or lower than in normal samples, while only two cancers had lower or equal expression as in normal samples ( Figure 3a) . The expression in the remaining six cancers ranged from 2.8-to 15-fold higher than normal (Figure 3a ), indicating that overexpression levels varies widely and can be further classified as mild, moderate or strong. We define mild overexpression as an expression ranging from 1.1-to 2.9-fold, the expression in normal breast tissue, moderate overexpression as an expression ranging from three-to 10-fold the expression in normal tissue and high overexpression as an expression ranging Figure 3c ). Skp2B expression was not detected above background within the 40 cycles of real time RT-PCR in the two normal breast samples or in two of the benign tumors. As Skp2 mRNA was detected in these samples confirming RNA integrity, these observations therefore support our finding using cell lines that endogenous expression of Skp2 is higher than Skp2B. Skp2B expression was, however, detected in one of the benign tumors and therefore this level of expression was set at a value of 1, such that overexpression is defined as an expression level higher than the expression detected in the benign tumor. Skp2B overexpression was also detected in six out of eight cancers and ranged from 1.6-to 20-fold, the level of expression in the benign tumor. Using the same classification as we used for Skp2 overexpression, we found that 37.5% (3/8) cancers overexpressed Skp2B mildly, none overexpressed at moderate level while 37.5% (3/8) strongly overexpressed Skp2B (Figure 3c ). We conclude that both Skp2 and Skp2B are overexpressed in breast cancers. When the expression of Skp2 and Skp2B was compared across all specimens, Skp2 expression was found to be 6.9-fold higher than the levels found in normal and benign samples, while Skp2B expression was nine-fold higher. Although suggestive, this difference did not reached statistical significance. However, when moderate and strong overexpression is considered, the average overexpression of Skp2 is 8.9-fold compared to 15.8-fold for Skp2B and as this difference reached statistical significance (P ¼ 0.00014), it suggests that Skp2B is overexpressed at higher levels than Skp2.
Cytoplasmic staining of Skp2B in breast cancer
Skp2 is a nuclear protein (Signoretti et al., 2002) , while we previously showed that Skp2B localizes to the cytoplasm (Ganiatsas et al., 2001) . Immunohistochemical analysis using an antibody that recognizes both Skp2 and Skp2B has revealed the presence of cytoplasmic staining in breast cancers (Signoretti et al., 2002) , although the percentage of cytoplasmic versus nuclear staining was not reported in this study. We therefore aimed at taking advantage of the differential localization of Skp2 and Skp2B to further estimate the relative frequency of overexpression of the two isoforms in breast cancers. Sections from 37 breast cancers were analysed by immunohistochemistry using an antibody that recognizes both Skp2 and Skp2B. Nuclear and cytoplasmic staining was assessed according to both the extent and the intensity of the staining. The extent ranges on a scale from 0 to 5 where a score of 0 indicated less than 10% of the cells were stained, 1 for 11-25%, 2 for 26-50%, 3 for 51-75%, 4 for 76-90% and 5 for more than 90% of the cells. The intensity was scored on a scale from 0 to 3 where 0 is negative and 3 is the strongest intensity of staining. The score for the extent and intensity was then added and considered weak if the total score was between 1 and 3, moderate between 4 and 6 and strong when above 7. Cancer sections were considered positive for staining if they scored either moderate or strong (Figure 4a ). In our study, 60% of cases were considered positive with 30% scored as moderate and 30% as strong (Figure 4b) . Further, 41%
Figure 3 Skp2 and Skp2B overexpression in breast cancers. In total, 100 ng total mRNA from normal breast tissues (2 Â ), benign breast tumors (3 Â ) and breast cancers (8 Â ) were used for specific Skp2 (a) or Skp2B (b) amplification by real-time RT-PCR. The highest level of Skp2 expression detected in the normal tissues was set at a value of 1 and the expression in all other samples determined relative to this value. For Skp2B, as no expression was detected in the normal samples, the level of expression detected in the benign tumor B1 was set at a value of 1 and Skp2B expression in all other samples determined relative to this value. (c) Subclassification of Skp2 and Skp2B overexpression in breast cancers Skp2B is overexpressed in breast cancer S Radke et al of the staining was nuclear and cytoplasmic and 59% of the staining was exclusively cytoplasmic (Figure 4a and c). Exclusive nuclear staining was observed in only 5% of cases and was not included in the positive population as the extent was less than 10% of cells with an intensity score of 2 or 3 resulting in a final score below 4. To test the possibility that the cytoplasmic staining could be due to abnormal staining of Skp2 in the cytoplasm due to its overexpression, 293T and MCF-7 cells were transfected with a plasmid expressing Skp2 and its localization determined by immunofluoresence. Skp2 staining was found to be exclusively nuclear in both cell lines (Figure 4d ) despite the fact that Skp2 mRNA levels were 400-to 800-fold higher as determined by real time RT-PCR (data not shown) upon transfection of Skp2. This result suggests that the cytoplasmic staining is due to Skp2B rather than aberrant Skp2 staining due to overexpression.
Skp2B expression does not affect p27 levels
The role of Skp2 on the ubiquitination and subsequent degradation of the Cdk inhibitor p27 has been well documented (Carrano et al., 1999; Sutterluty et al., 1999) . The C-terminal domain of Skp2 was found to stabilize the binding between Skp2 and Skp1 (Schulman et al., 2000) , while the leucine-rich repeats (LLR) are thought to be required for binding to the substrate. As Skp2B sequence has a different C-terminal domain and lacks the last three LRR, it may not promote p27 ubiquitination. To test this hypothesis, the level of p27 was determined by immunohistochemistry in breast cancer sections characterized by exclusive cytoplasmic staining. We found strong p27 nuclear staining in these sections ( Figure 5a ) suggesting that Skp2B does not affect p27 levels. To further assess the effect of Skp2B on p27 levels, 293T cells were transfected with either Skp2 or Skp2B expressing plasmids and the levels of p27 determined by Western blotting. We found that while p27 levels were decreased upon Skp2 transfection (Figure 5b ), p27 levels were identical in both the untransfected and Skp2B transfected cells (Figure 5b ). These results therefore support our finding of strong p27 staining in breast cancer sections and suggest that Skp2B overexpression does not affect p27.
Skp2B is an unstable protein
We reproducibly observed that upon transfection of Skp2 and Skp2B expression plasmids, the level of Skp2B protein is lower compared to Skp2 despite the fact that both cDNAs are expressed under the control of the same promoter. We estimated that approximately 10-fold more Skp2B expression plasmid is required than Skp2 to obtain similar level of protein (Figure 5b compare 10 mg Skp2B to 1 mg Skp2). This observation suggests either that Skp2B mRNA or protein is more unstable than that of Skp2. In agreement with the later possibility, upon expression of Skp2 and Skp2B to similar levels in 293T cells (Figure 6a , top panel), a laddering of protein bands that are immunoreactive to Skp2 antibodies is detected in lanes where Skp2B was transfected and its intensity was increased by the proteasome inhibitor LLnL (Figure 6a , lower panel).
In contrast, such laddering was much less intense in lanes transfected with Skp2. This observation suggests that Skp2B may be rapidly ubiquitinated. To test directly the ability of Skp2B to be ubiquitinated, 293T cells were transfected with an Skp2B expression plasmid in the presence or absence of a plasmid expressing Myctagged ubiquitin. We found that immunoprecipitation of Skp2B using an antibody that recognizes both Skp2 and Skp2B is associated with polyubiquitinated chains, and that incubation with the proteasome inhibitor LLnL enhances the detection of these polyubiquitinated forms of Skp2B (Figure 6b ). Therefore, this result suggests that Skp2B is rapidly turned over and may explain the difficulty in detecting a faster migrating band in Skp2 Western blotting despite the fact that 293T cells express similar levels of Skp2 and Skp2B mRNA as determined by real time RT-PCR (data not shown). To address directly the half-life of Skp2 and Skp2B, we established stable clones expressing high levels of Skp2B mRNA using the breast cancer cell line MCF-7. Upon screening these clones for Skp2B expression by Western blotting, we identified one clone expressing Skp2 and Skp2B proteins at similar levels and in which Skp2B could be distinguished from Skp2 due to its faster migration ( Figure 6c ). We therefore took advantage of this clone to determine the relative half-life of Skp2 and Skp2B using cycloheximide to inhibit global protein synthesis (Figure 6d ). We found that in average while the half-life of Skp2 is 90 min in unsynchronized cells, the half-life of Skp2B is 30 min (Figure 6e ). This observation indicates that the turnover of Skp2B is approximately three-fold faster than that of Skp2 and is in agreement with our finding that Skp2B is ubiquitinated at a higher rate than Skp2.
Skp2B overexpression promotes xenograft formation
To determine the effect of Skp2B overexpression on the growth of breast cancer cells, we established stable clones expressing Skp2 or Skp2B in the breast cell line T47-D, and tested their ability to form xenografts in nude mice. This cell line was chosen as it is characterized by normal expression level of Skp2 and low expression of Skp2B (Figure 2 ). In each case, a minimum of three independent clones was pooled together for injection in nude mice and the level of expression tested by Western blot (Figure 7a ). Three groups of seven mice each were created, group 1 received T47-D cells, group 2 received T47D-Skp2 and group three received T47-D-Skp2B expressing cells. Following injection of cells into nude mice, tumors were allowed to grow for 7 days before the first measurement and tumor volumes were measured weekly thereafter. We found that the average tumor volume in the T47-D and T47-D-Skp2 xenografts was not significantly different, while the growth of T47-DSkp2B cells was faster than the other two groups (Figure 7b ). Statistical analysis of the tumor volumes in the T47-D or T47-D-Skp2 versus T47-D-Skp2B revealed a statistically significant difference in tumor volume between these groups at weeks 4, 5 and 6 (Figure 7c ). Figure 7d shows the tumor volume of individual mice in each group ranging from the smallest tumor to the largest tumor in each group at week 6. We found that theT47-D-Skp2B group contained five tumors of similar or greater volume compared to the largest tumor in the other two groups. In addition, the levels of Skp2, Skp2B, p27 and p21 were determined in a representative xenograft of each group. Western blot using anti-Skp2 antibody confirmed the sustained expression of Skp2 and Skp2B during the 6 weeks incubation in nude mice . Further, we found that p27 and p21 levels in the Skp2B overexpressing xenograft were identical to the level in the T47-D xenograft (Figure 7e , middle and lower panels). This observation indicates that Skp2B overexpression promotes xenograft formation independently of an effect on p27 or p21, and therefore supports the hypothesis that the overexpression of Skp2B observed in primary breast cancers does contribute to tumor growth. In order to gain some insight into the mechanism by which Skp2B promotes xenograft formation, we first tested whether Skp2B accelerates the growth rate of T47-D cells in vitro. T47-D and T47-D-Skp2B cells were plated and the doubling time determined over a period of 3 days. However, we found that T47-D and T47-DSkp2B cells grew at a similar rate (data not shown), suggesting that Skp2B overexpression does not exert its effect by accelerating proliferation. As the effect of Skp2B on the xenograft formation could also be explained by a decrease in cell death, we next tested the effect of Skp2B overexpression on cell death using UV light as an apoptotic signal. We found that while 30 and 40 J/m 2 of UV irradiation reduced the viability of T47-D-Skp2 cells, Skp2B overexpression protected cells from UV treatment (Figure 8a ) suggesting that Skp2B overexpression may have an antiapoptotic effect. To further analyse the potential interaction between DNA damage and Skp2B, the effect of increasing doses of UV light on the level of endogenous Skp2/2B in 293T and T47D cells was tested by Western blot (Figure 8b ). Using an antibody that recognizes both Skp2 and Skp2B, we found that lower doses of irradiation (2-30 J/m 2 ) but not higher doses (>40 J/m 2 ) of irradiation led to an increase in Skp2 and/or Skp2B levels (Figure 8b ). To determine which of the two isoforms is affected by irradiation, 293T cells were transfected or not with Skp2B plasmids and the cells subjected to low dose (5 J/m 2 ) of irradiation (Figure 8c ). We found that transfection of Skp2B plasmid led to an enhanced signal following irradiation compared to Skp2B transfection alone, indicating that irradiation increases the level of Skp2B rather than Skp2. Finally, as we found that Skp2B protein is an unstable protein due to its ubiquitination, we next asked whether irradiation affects the rate of Skp2B ubiquitination. We found that while Skp2B was ubiquitinated in the absence of irradiation, the level of Skp2B ubiquitination was reduced upon exposure to a low dose of UV (Figure 8d ). This result suggests that the increase in Skp2B levels following low doses of UV irradiation is due to Skp2B protein stabilization.
Discussion
We have isolated Skp2B, a new isoform of the F-box protein Skp2 and found that it localizes to the cytoplasm. Here, we show that Skp2B mRNA is elevated in breast cancer cell lines and in primary breast cancers. Further, we have shown that cytoplasmic staining of Skp2 using an antibody that recognizes both Skp2 and Skp2B is frequent in breast cancers, strongly suggesting that the Skp2B spliced form is overexpressed in breast cancers, either predominantly or in addition to Skp2. In the absence of an Skp2B specific antibody, the possibility that Skp2 is aberrantly localized to the cytoplasm in some cancer samples cannot be entirely ruled out. However, the fact that overexpression of Skp2 by transfection in cell lines does not lead to any detectable Skp2 in the cytoplasm argues against the possibility that Skp2 overexpression leads to a leaky staining in the cytoplasm. Further, we have previously reported that a mutant of Skp2 where the entire C-terminal domain has been deleted still localized to the nucleus (Ganiatsas et al., 2001) . This observation suggests that cytoplasmic retention is an active process that requires the C-terminal domain of Skp2B. In addition, to our knowledge, no mutation leading to the aberrant cytoplasmic localization of Skp2 has been reported and so Skp2B overexpression is the only known situation that results in cytoplasmic localization.
Considering that Skp2B was found to be an extremely unstable protein, it seems unlikely that overexpression of Skp2B mRNA would be sufficient to led to the strong accumulation of Skp2B in the cytoplasm as detected by immunohistochemistry. However, Skp2B protein stabilization may represent a more potent mechanism for the accumulation of Skp2B in cancer samples. In agreement with this hypothesis, we found that Skp2B protein is transiently stabilized by low doses of DNA damage suggesting that while its levels are tightly restricted, Skp2B may be stabilized in response to specific signals including UV irradiation. This observation raises the possibility that one function of Skp2B is to protect cellular integrity under low level of stress. In addition, this observation also raises the possibility that in some cancers, Skp2B is abnormally stabilized and that its accumulation may prevent cell death and contribute to cancer progression or formation.
In support of a role of Skp2B in breast cancer progression, we found that Skp2B overexpression promotes xenografts formation in a p27-independent manner. Therefore, the substrates of Skp2B-mediated ubiquitination remain to be determined and their identification will help in clarifying how Skp2B overexpression promotes growth in vivo. Alternatively, we cannot rule out the possibility that Skp2B may be acting in an ubiquitinationindependent manner, although this possibility appears unlikely in view of the well-defined role of F-box proteins in this process. The identification of proteins associated with Skp2B will be needed to resolve this issue.
While several studies have reported the inverse correlation between Skp2 and p27 levels in various cancer types, in other studies, this correlation was not as well defined. Notably, in prostate cancer in the AfricanAmerican population, Skp2 cytoplasmic staining was found to be predominant and the lack of correlation between Skp2 and p27 levels in a large number of these cases led the authors to conclude that Skp2 expression in prostate cancer pathogenesis might not be exclusively related to p27 degradation (Drobnjak et al., 2003) . Two additional studies, one in Kaposi's sarcoma and another in cervical cancer, found no correlation between Skp2 expression and loss of p27. Further, both of these studies reported a significant percentage of cytoplasmic staining of Skp2, which also suggests that Skp2B overexpression in these tumors may explain their observations (Penin et al., 2002; Dowen et al., 2003) . Clearly, the results presented here offer a potential explanation for these apparent contradictions and will help in clarifying these issues in the future.
Finally, studies of the SCF ubiquitin ligases in the last recent years have revealed the immense complexity in the cellular function of these complexes. The isolation of a cytoplasmic isoform of the F-box protein Skp2 and the demonstration of its potential oncogenic role as shown here indicate that more surprises lay ahead.
Materials and methods

RNA extraction and real time RT-PCR
RNA was extracted from cell lines and breast tissues using (Skp2B), data acquisition. Melting curve data between 65 and 951C were acquired at the end of the RT-PCR to ensure the specific detection of one specific PCR product. The same upstream primer (5 0 -TCA ACT ACC TCC AAC ACC TAT CAC-3 0 ) designed from the common cDNA sequence was used for Skp2 and Skp2B amplification. The downstream primer sequences were taken from the diverse cDNA sequence of the C-termini (Skp2-primer: 5 0 -GAC AAC TGG GCT TTT GCA GT-3 0 ; Skp2B-primer: 5 0 -CAG ATT ACT CTG ACA TGT TGG C-3 0 ). In total, 20 pmol of each primer were used per measurement. The amplification resulted in fragments of 271 bp (Skp2) or 184 bp (Skp2B).
Immunohistochemistry
For immunostaining of paraffin sections, an anti-Skp2 antibody (Zymed Inc., South San Francisco, CA, USA) was used at a dilution of 1 : 100 and the rabbit anti-p27 antibody (Santa Cruz, was used at a dilution of 1 : 50.
Immunohistochemical staining was performed on archival formalin-fixed tissue sections (3-5 mm), which were dewaxed and rehydrated in water. Antigen retrieval was performed in a Sharp Carousel (600 W) microwave oven by bringing sections to boil in 10 mM sodium citrate pH 6.0 and then incubating for 20 min on medium (50%) power. Endogenous peroxidase activity was blocked with 3% (v/v) hydrogen peroxide for 10 min. All buffer washes between antibody incubations were with 50 mM Tris-HCl pH 7.6. Immunostaining was performed using the Histostain Plus broad spectrum kit (Zymed). The Skp2 and p27 antibodies were incubated for 60 min at room temperature and followed by biotinylated secondary antibodies for 60 min. Sections were then counterstained in haematoxylin for 5 s and mounted with DPX.
Immunofluoresence
Cells were plated in six-well tissue culture plates containing a sterile coverslip at a density of 2.5 Â 10 5 cells per well. The
Skp2B is overexpressed in breast cancer S Radke et al following day, cells were transfected for 24 h. For staining the cells were fixed in 4% paraformaldehyde-PBS for 15 min at RT, then permeabilized using PBS containing 0.1% Triton X-100/0.5% BSA for 5 min at RT. A blocking solution of 2% BSA/PBS was applied to the cells for 15 min at RT. Primary and secondary antibodies were prepared in 2% BSA/PBS at a concentration of 1 : 100 and applied to cells for 1 h at RT. Following antibody incubations, cells were washed with 1 ml of 0.05% Triton X-100/PBS for 2 min, then rinsed in PBS. Coverslips were mounted on glass slides, in Citifluor AF1 (Alltech) mounting solution.
Transfection, protein extraction and immunoprecipitation
293T and T47-D cells were transfected by lipofection using the FuGENEt 6 system as described by the manufacturer (Boehringer Mannheim) with 2 mg of pCDNA3-Skp2, pCDNA3-Skp2B or pCDNA3-Myc-ubiquitin. Protein extraction and immunoprecipitation were performed as described elsewhere (Ganiatsas et al., 2001) . For inhibition of the 26S proteosome, cells were treated with the peptide aldehyde leucinyl-leucinyl-norleucinyl (LLnL) solubilized in DMSO at a final concentration of 100 mM for 18 h. Following immunoprecipitation, proteins were resolved on 8 or 10% polyacrylamide gels, transferred onto nitrocellulose membranes, subjected to standard Western blotting analysis and visualized using ECL (Amersham Life Science). For detection of Skp2, the mouse antibody (Zymed, clone 8D9) was used at a dilution of 1 : 100. For detection of p27 and p21 rabbit polyclonal antibody N-20 and H164 (Santa Cruz) was used at a dilution of 1 : 100. For the detection of tubulin, the anti-a-tubulin mouse monoclonal antibody (Sigma) was used at a dilution of 1 : 3000.
Establishment of stable cell lines
T47-D and MCF-7 were grown in RPMI or DMEM medium, respectively, supplemented with 10% fetal calf serum, insulin (100 IU/ml), and antibiotics (Life Technologies, Inc.). cDNA encoding the coding sequence of Skp2 or Skp2B was cloned in the pCDNA3 expression vector (Invitrogen). Transfections of Skp2-pcDNA3 or Skp2B-pcDNA3 plasmids into T47-D cells were performed using the FuGENEt 6 system, as described by the manufacturer (Boehringer Mannheim). Clones stably expressing Skp2, Skp2B or empty vector were selected using G418 at a final concentration of 0.78 mg/ml and screened for the levels of Skp2 or Skp2B expression by Western blot. In each case, a minimum of three individual clones was pooled together in order to avoid indirect effect due to the site of integration of the plasmid in individual clones. The pooled clones are referred to as T47-D, T47-D-Skp2 and T47-D-Skp2B cells in the xenograft experiment. Stable clones expressing Skp2B in MCF-7 were obtained using the same method as described for T47-D cells. However, only one MCF-7-Skp2B clone expressed Skp2B at the same level of endogenous Skp2 and therefore this clone was used to determine the relative half-life of each isoform. For the cycloheximide chase, cycloheximide was added to a concentration of 20 mg/ml for the indicated period of time and Skp2/2B proteins detected by Western blot.
Xenografts implantation
Balb/c nude mice (8 weeks old) were used for the xenograft study. Prior to injection of T47-D, T47-D-Skp2 and T47-DSkp2B cells, a 17-b estradiol pellet (0.72 mg/ml) was inserted subcutaneously in the upper back of each mouse. To insert the estradiol pellet, mice were anesthetized using methoxyflurane. A small incision was made and the pellet inserted using precision trochar. The incision was sealed using an autoclip.
Prior to the subcutaneous injection, 5 Â 10 6 cell pellets were mixed with an equal volume of matrigel (Basement Membrane Matrix, Becton Dickinson, cat#354234). The mixture was injected subcutaneously in the lower back of each animal using a 26G needle.
Statistical methods
Tumor volumes in all groups were compared by the Wilcoxon rank sum test for each weekly measurement. All tests were two-sided.
